Tags

Type your tag names separated by a space and hit enter

Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
Nephron. 1989; 53(3):194-200.N

Abstract

The effect of intravenous 1 alpha(OH)D3 on circulating intact parathyroid hormone (PTH) and COOH-terminal immunoreactive PTH was examined in 21 patients on chronic hemodialysis. The patients were treated for 3 months with increasing doses of 1 alpha(OH)D3 under careful control of serum Ca2+. 1 alpha(OH)D3 was given intravenously at doses of up to 4 micrograms three times a week, and blood samples were obtained every week, including 1 week before treatment (basal control). No patients were treated with oral vitamin D metabolites. At the end of the study intact PTH levels were reduced by an average of 67 +/- 6%, and COOH-terminal immunoreactive PTH levels were reduced by 35 +/- 6%. Serum Ca2+ was kept within normal levels, but showed a slight increase from 1.17 to 1.30 mmol/l. An effect of calcium on PTH secretion could not be excluded, but an effect of 1 alpha(OH)D3, independent of serum Ca2+ was also found. This effect may be mediated by 1,25(OH)2D3, assuming a large capacity of the 25-hydroxylase in the liver to convert 1 alpha(OH)D3 to 1,25(OH)2D3. Also, the parathyroid glands may possess receptors for 1 alpha(OH)D3 with an effect similar to that established for the 1,25(OH)2D3 receptors. Thus, although the exact mechanisms of the action of 1 alpha(OH)D3 have not yet been completely clarified, it is concluded that intravenous administration of 1 alpha(OH)D3 may be of benefit in the treatment of secondary hyperparathyroidism of uremia.

Authors+Show Affiliations

Medical Department P, Rigshospitalet, Copenhagen, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2797340

Citation

Brandi, L, et al. "Effect of Intravenous 1-alpha-hydroxyvitamin D3 On Secondary Hyperparathyroidism in Chronic Uremic Patients On Maintenance Hemodialysis." Nephron, vol. 53, no. 3, 1989, pp. 194-200.
Brandi L, Daugaard H, Tvedegaard E, et al. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron. 1989;53(3):194-200.
Brandi, L., Daugaard, H., Tvedegaard, E., Storm, T., & Olgaard, K. (1989). Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron, 53(3), 194-200.
Brandi L, et al. Effect of Intravenous 1-alpha-hydroxyvitamin D3 On Secondary Hyperparathyroidism in Chronic Uremic Patients On Maintenance Hemodialysis. Nephron. 1989;53(3):194-200. PubMed PMID: 2797340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. AU - Brandi,L, AU - Daugaard,H, AU - Tvedegaard,E, AU - Storm,T, AU - Olgaard,K, PY - 1989/1/1/pubmed PY - 1989/1/1/medline PY - 1989/1/1/entrez SP - 194 EP - 200 JF - Nephron JO - Nephron VL - 53 IS - 3 N2 - The effect of intravenous 1 alpha(OH)D3 on circulating intact parathyroid hormone (PTH) and COOH-terminal immunoreactive PTH was examined in 21 patients on chronic hemodialysis. The patients were treated for 3 months with increasing doses of 1 alpha(OH)D3 under careful control of serum Ca2+. 1 alpha(OH)D3 was given intravenously at doses of up to 4 micrograms three times a week, and blood samples were obtained every week, including 1 week before treatment (basal control). No patients were treated with oral vitamin D metabolites. At the end of the study intact PTH levels were reduced by an average of 67 +/- 6%, and COOH-terminal immunoreactive PTH levels were reduced by 35 +/- 6%. Serum Ca2+ was kept within normal levels, but showed a slight increase from 1.17 to 1.30 mmol/l. An effect of calcium on PTH secretion could not be excluded, but an effect of 1 alpha(OH)D3, independent of serum Ca2+ was also found. This effect may be mediated by 1,25(OH)2D3, assuming a large capacity of the 25-hydroxylase in the liver to convert 1 alpha(OH)D3 to 1,25(OH)2D3. Also, the parathyroid glands may possess receptors for 1 alpha(OH)D3 with an effect similar to that established for the 1,25(OH)2D3 receptors. Thus, although the exact mechanisms of the action of 1 alpha(OH)D3 have not yet been completely clarified, it is concluded that intravenous administration of 1 alpha(OH)D3 may be of benefit in the treatment of secondary hyperparathyroidism of uremia. SN - 1660-8151 UR - https://www.unboundmedicine.com/medline/citation/2797340/Effect_of_intravenous_1_alpha_hydroxyvitamin_D3_on_secondary_hyperparathyroidism_in_chronic_uremic_patients_on_maintenance_hemodialysis_ L2 - http://www.diseaseinfosearch.org/result/8597 DB - PRIME DP - Unbound Medicine ER -